Welcome to PRI

Founded in 2002, the Pharmaceutical Research Institute (PRI) at Albany College of Pharmacy and Health Sciences is a center for drug discovery and development.

PRI investigators possess expertise in fields that include nanotechnology, medicinal chemistry, molecular biology, and cell biology. Areas of focus include: hematology/oncology, cardiovascular (dyslipidemia), ophthalmology, vascular diseases, neurology, and inflammation.As part of its mission, PRI is also engaged in teaching and learning. Pharmacy students, graduate students, and visiting scholars from around the world visit the Institute to conduct research and learn the latest advances across a wide range of therapeutic areas.

PRI Celebrates 15 Years !!

Left to Right: W. Li, K. Godugu, S.A. Mousa, P. Phillips. M. Jayaraman, D. Bharali, S. Thangirala,

M. Rajabi, B. Hay, K. Keating, O. Karakus

1-DAY NANOMEDICINE CONFERENCE WAS HELD ON ACPHS CAMPUS

SEPTEMBER 25, 2017 – Click here for full brochure and schedule 

POSTER WINNERS FROM THE CONFERENCE:

Left to right, Dr. Weikun Li (PRI), Dr. Mousa, Dr. Kavitha Godugu (PRI)

Dr. Li’s poster was titled, “Formulation and pharmacokinetics of diamino propane tetraiodothyroacetic acid-conjugated biodegradable polymeric nanoparticles and anti-angiogenesis efficacy” with coauthors Murat Yalcin, Dhruba J. Bharali, Quishan Lin, Kavitha Godugu, and Shaker A. Mousa.

Dr. Godugu’s poster was titled, “Anticancer Efficacy of P-bi-TAT, A Novel Thyrointegrin Receptor Antagonist in Solid Tumors” with coauthors Sudha Thangirala, Mehdi Rajab, and Shaker A. Mousa.

Recent Publications

  • Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

    T Sudha, DJ Bharali, M Yalcin, NHE Darwish, M Debreli Coskun, KA Keating, H-Y Lin, PJ Davis, SA Mousa (2017)
    Nanomedicine 12(3):195-205.

    Read more
  • Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery

    W Li, M Yalcin, Q Lin, MM Ardawi, SA Mousa (2017)
    Journal of Controlled Release 248:117-124

    Read more